KFDA

MediThinQ Marks Milestone as First Asian Startup to Globally Launch XR Surgical Displays, Securing Key Partnerships and Multimillion-Dollar Investment

Retrieved on: 
Mardi, février 20, 2024
FDA, KFDA, IPO, PMDA, Gold, XR, Medtronic, Partnership, Pharmaceutical industry

SINGAPORE, Feb. 20, 2024 /PRNewswire/ -- MediThinQ, a pioneering Korean startup specialising in extended reality (XR) wearable displays for surgery, is making waves as the first Asian startup to globally launch XR surgical displays.

Key Points: 
  • SINGAPORE, Feb. 20, 2024 /PRNewswire/ -- MediThinQ, a pioneering Korean startup specialising in extended reality (XR) wearable displays for surgery, is making waves as the first Asian startup to globally launch XR surgical displays.
  • The company has successfully secured significant deals with industry giants, including Medtronic USA and Japan, marking a substantial milestone in its international expansion efforts.
  • In tandem, MediThinQ has secured a multimillion-dollar investment from JLK Technology, a Singapore-headquartered medical devices manufacturer, who will also help accelerate MediThinQ's mass production as its appointed manufacturer.
  • MediThinQ's XR solutions present critical information directly in from of the surgeon's eyes, eliminating the need to divert attention to screens.

MediThinQ Marks Milestone as First Asian Startup to Globally Launch XR Surgical Displays, Securing Key Partnerships and Multimillion-Dollar Investment

Retrieved on: 
Mardi, février 20, 2024
FDA, KFDA, IPO, PMDA, Gold, XR, Medtronic, Partnership, Pharmaceutical industry

SINGAPORE, Feb. 20, 2024 /PRNewswire/ -- MediThinQ, a pioneering Korean startup specialising in extended reality (XR) wearable displays for surgery, is making waves as the first Asian startup to globally launch XR surgical displays.

Key Points: 
  • SINGAPORE, Feb. 20, 2024 /PRNewswire/ -- MediThinQ, a pioneering Korean startup specialising in extended reality (XR) wearable displays for surgery, is making waves as the first Asian startup to globally launch XR surgical displays.
  • The company has successfully secured significant deals with industry giants, including Medtronic USA and Japan, marking a substantial milestone in its international expansion efforts.
  • In tandem, MediThinQ has secured a multimillion-dollar investment from JLK Technology, a Singapore-headquartered medical devices manufacturer, who will also help accelerate MediThinQ's mass production as its appointed manufacturer.
  • MediThinQ's XR solutions present critical information directly in from of the surgeon's eyes, eliminating the need to divert attention to screens.

‘AlignMiracle’ Makes Waves in the World of Direct Clear Aligner, Featured in the Prestigious International Clinical Journal, JCO

Retrieved on: 
Lundi, décembre 4, 2023
Research, Apps, Applications, Technology, Medical Devices, Publishing, Dental, Communications, Software, Health, Science, JCO, Orthodontics, ODS, Journal of Clinical Orthodontics, Dentist, History, Patient, Multimedia, Journal, Doctor of Philosophy, FDA, KFDA, CMO, Certification, Publication, Dentistry

ODS Co., Ltd. , a leading provider of Direct Clear Aligner (also known as “Direct Print Aligner”), today announced the publication of treatment cases using direct clear aligners in the October 2023 issue of the Journal of Clinical Orthodontics (JCO), one of the most respected publications in the field of orthodontics.

Key Points: 
  • ODS Co., Ltd. , a leading provider of Direct Clear Aligner (also known as “Direct Print Aligner”), today announced the publication of treatment cases using direct clear aligners in the October 2023 issue of the Journal of Clinical Orthodontics (JCO), one of the most respected publications in the field of orthodontics.
  • Founded in 1967, JCO is an esteemed international academic journal with a rich history of over five decades.
  • It serves as a platform for disseminating the latest techniques and innovative approaches in orthodontics.
  • With its comprehensive coverage and global reach, JCO has garnered a loyal readership among orthodontic clinicians worldwide.

Maypharm Introduces its whole Lineups with Newly Launched products including METOO, HAIRNA, and SEDY FILL

Retrieved on: 
Mercredi, août 30, 2023
Rejuvenation, Filler (linguistics), Safety, Cosmetics, Skin care, KFDA, Pharmaceutical industry

SEOUL, South Korea and NEW YORK, Aug. 30, 2023 /PRNewswire/ -- Maypharm Co., Ltd. introduces its whole lineups with newly launched products including METOO, HAIRNA, and SEDY FILL.

Key Points: 
  • SEOUL, South Korea and NEW YORK, Aug. 30, 2023 /PRNewswire/ -- Maypharm Co., Ltd. introduces its whole lineups with newly launched products including METOO, HAIRNA, and SEDY FILL.
  • Maypharm is a global company founded in 2015, specializing in cosmetic medicine and dermocosmetic products for skin care and rejuvenation.
  • Maypharm is committed to providing innovative cosmetic solutions with the highest standards for safety and efficacy, exceeding both patient and provider expectations.
  • Maypharm offers specialty medical supplies and medical-grade skin care products, including dermal fillers, botulinum toxin, mesotherapy products, cosmetics, and more.

Biomerica Reports Financial Results for Fiscal 2023 Second Quarter Ended November 30, 2022

Retrieved on: 
Vendredi, janvier 13, 2023
API, Constipation, GI, Stomach, American College, Ministry, IBS, FDA, Hereditary diffuse gastric cancer, Abdominal pain, Health, Kingdom, Walmart, Breast, Woman, KFDA, Food, American College of Gastroenterology, Patient, Diet, EZ, Science, MENA, ACG, United Arab Emirates, Degenerative disease, Physician, COVID-19, Pain, Pharmaceutical industry, Birth control

IRVINE, Calif., Jan. 13, 2023 (GLOBE NEWSWIRE) -- IRVINE, CABiomerica, Inc. (Nasdaq: BMRA ), (the “Company”) a global provider of advanced medical products, today reported its second quarter fiscal 2023 financial results for the period ended November 30, 2022.

Key Points: 
  • IRVINE, Calif., Jan. 13, 2023 (GLOBE NEWSWIRE) -- IRVINE, CABiomerica, Inc. (Nasdaq: BMRA ), (the “Company”) a global provider of advanced medical products, today reported its second quarter fiscal 2023 financial results for the period ended November 30, 2022.
  • Excluding sales of Covid-19 products, revenues increased 8% for the quarter ended November 30, 2022 as compared to the three months ended November 30, 2021.
  • Gross margin during the quarter ended November 30, 2022 increased to 24% as compared to a gross margin of 17% in the second fiscal quarter 2022.
  • Cash and cash equivalents at the end of the fiscal second quarter was $5.1 million, a net decrease of $0.8 million during the first six-months of fiscal 2023.

Charles River and Rznomics Announce RNA-based Anticancer Gene Therapy Manufacturing Alliance

Retrieved on: 
Mercredi, janvier 18, 2023
Research, Medical Devices, Genetics, Clinical Trials, Biotechnology, Health, Pharmaceutical, Science, Oncology, Liver cancer, Partnership, Hepatocellular carcinoma, Cognate, DNA, Reverse transcriptase, ATMP, CDMO, MFDS, HCC, Patient, CRL, Korean Ministry of Culture, NYSE, KFDA, US Foods, FDA, Therapy, Transfection, RNA, Corporation, Vaccine, Pharmaceutical industry, Food, IND

Charles River Laboratories International, Inc. (NYSE: CRL) and Rznomics Inc. , a South Korea-based biopharmaceutical company specialized in the development of RNA-based gene therapeutics, today announced a viral vector contract development and manufacturing organization (CDMO) partnership.

Key Points: 
  • Charles River Laboratories International, Inc. (NYSE: CRL) and Rznomics Inc. , a South Korea-based biopharmaceutical company specialized in the development of RNA-based gene therapeutics, today announced a viral vector contract development and manufacturing organization (CDMO) partnership.
  • Rznomics will leverage Charles River’s viral vector CDMO experience to initiate clinical development of its RNA-based anticancer gene therapy in liver cancer patients.
  • RZ-001 is the first ribozyme-based RNA reprogramming approach approved by the US Food and Drug Administration (FDA) for evaluation in patients.
  • Charles River has standardized protocols for cell culture, transfection, and downstream purification, as well as a validated platform process with a proven track record.

Biomerica Receives KFDA and Ministry of Health Approval for Colorectal Screening and Breast Screening Tests in Saudi Arabia and UAE

Retrieved on: 
Jeudi, décembre 8, 2022
Breast cancer, Woman, Colorectal cancer, Physician, Breast, Incidence, Ministry, Prevalence, Food, FDA, Colon, Sale, Cancer, Female, Emirates, Environment, EZ, Archive, Kingdom, Ministry of Health (Saudi Arabia), Biomedical technology, KFDA, Research, Patent, Government agency, United Arab Emirates, Public health, Medical imaging, Health

It’s the only test with no stool handling and suitable for national screening campaigns due to its convenience and cost-effectiveness.

Key Points: 
  • It’s the only test with no stool handling and suitable for national screening campaigns due to its convenience and cost-effectiveness.
  • The Aware® Breast Self Exam is a revolutionary way for women to enhance the tactile sensitivity to feel abnormalities in breast tissue.
  • About 80% of breast cancer cases are detected because women themselves notice changes in their breast (Cancer 2014; 120:20-5).
  • The Company's products are designed to enhance the health and well-being of people, while reducing total healthcare costs.

Gray Announces Management Changes

Retrieved on: 
Mardi, août 2, 2022
Honey, Raycom Sports, Region, KPDX, Sherman, WSMV, GLOBE, FOX, WMTV, WOIO, WUAB, KPTV, CW, NYSE, Fox, Gray Television, WLBT, CBS, WDBJ, WZBJ, KFDA, General manager, WBRC, Television, NBC, Senior, Joint Planning and Development Office, Grey, WAFB, MyNetworkTV, WTVM

ATLANTA, Aug. 02, 2022 (GLOBE NEWSWIRE) -- Gray Television, Inc. (Gray or we) (NYSE: GTN) today announced that, effective August 1st, Gray has streamlined the senior management of its television station operations including the promotion of several General Managers to new positions as Regional Vice President/General Manager.

Key Points: 
  • ATLANTA, Aug. 02, 2022 (GLOBE NEWSWIRE) -- Gray Television, Inc. (Gray or we) (NYSE: GTN) today announced that, effective August 1st, Gray has streamlined the senior management of its television station operations including the promotion of several General Managers to new positions as Regional Vice President/General Manager.
  • These professionals will continue managing their current local television stations as they assume oversight of additional Gray television stations.
  • Ted Fortenberry, the General Manager of WLBT (NBC) in Jackson, Mississippi, will now also oversee Grays television stations in Biloxi and Hattiesburg, Mississippi, and Monroe, Louisiana.
  • The changes announced today result from the decision of Senior Vice President-Local Media Tim Ingram to resign his position to pursue other opportunities outside of Gray Television.

Legend Capital Portfolio Company: The Global-Leading AI Medical Imaging Company Lunit Goes Public Successfully

Retrieved on: 
Jeudi, juillet 21, 2022
Regulation of tobacco by the U.S. Food and Drug Administration, UNPRI, Diagnosis, Investment, Physician, Philips, Food, CEO, MDSAP, Solution, Liquid biopsy, Artificial intelligence, KFDA, USD, KOSDAQ, Cancer, Certification, CE, KAIST, Immunotherapy, Helmy Eltoukhy, Medical device, FDA, Patient, Breast cancer, Efficiency, BioMaPS Institute for Quantitative Biology, Health, Engineering, ESG, Growth, GE Healthcare, VC, AI, RMB, Fujifilm, Unimed, Technology

Lunit SCOPE is an AI biomarker for immunotherapy, providing therapy response information that can critically affect treatment outcomes for cancer patients.

Key Points: 
  • Lunit SCOPE is an AI biomarker for immunotherapy, providing therapy response information that can critically affect treatment outcomes for cancer patients.
  • For the past 4 years, Lunit not only has produced world-leading AI medical solutions but also gained its commercial value achieving rapid topline growth.
  • Legend Capital has invested heavily in companies that integrate technology and the medical industry and has kept betting on AI medical sectors.
  • In addition to Lunit, Legend Capital has also invested in AI medical companies such as Xbiome, an AI microbiome drug development company; StoneWise, an AI drug R&D platform; Deepwise, an AI medical imaging company; BioMap, a biocomputing platform; Deep Informatics ++, an AI medical pathology diagnosis company; and Unimed, an AI brain diagnosis and treatment platform.